Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Vtama is projected to contribute $150 million in 2025 revenue, supported by its new label approval for atopic dermatitis. Nexplanon is expected to reach at least $1 billion in revenue for 2025. Q4 ...

So it was that Saturday 1st July was a busy day. Organon and Samsung Bioepsis were first to launch biosimilar Hadlima (adalimumab-bwwd) that day, at the sale price of $1,038 per carton containing ...

Biosimilars revenue declined 18% on both an ... pressure in the U.S. Performance was partially offset by sales of Hadlima® (adalimumab-bwwd) that have continued to ramp up since its July 2023 ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

After hours: February 14 at 7:59:52 PM EST Loading Chart for OGN ...

After hours: 7:59:52 p.m. EST ...

A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost ...